We designed this research with RA patients and now we're crowdsourcing the science with the community. The power to research firstline RA drugs is in your hands: Participate in this study! Fund. Share.
Tatyana Dobreva, PhD
Participate in this study!
Register today to receive enrollment information directly from ImYoo.
of people with rheumatoid arthritis fail to respond to first line therapy
of people with rheumatoid arthritis have adverse side effects to first line therapy
Rheumatoid arthritis patients have to go through a series of drugs before finding one that works for them. While trying out firstline drugs such as methotrexate, many patients experience a series of debilitating side-effects, such as nausea, fatigue, and infections, causing them to discontinue their usage. Currently, there are limited tests available to tell a patient whether a drug will work for them, which could potentially save them time, money, and prevent a painful experience. Tools such as single-cell RNA sequencing provide high-resolution snapshots into the behavior of many different immune cells in a person’s blood. By combining single-cell immune profiling and at-home capillary blood self-collection, we are looking to understand why first line of defense drugs work for some people and not others. For a behind-the-scenes view of how we made this study happen, check out our blog on Medium!
|Project Length||6-8 weeks|
|Goal||Our primary goal is to collect samples from rheumatoid arthritis patients starting a firstline therapy and use their high-resolution immune profiles to predict responders and non-responders. Our secondary goal is to track these patients before, during, and after their drug regimen to more precisely characterize why the drug is failing to work and why some patients experience more severe side-effects than others.|
|Research Type||Exploratory Research, Pre-clinical research|
Decentralizing immune studies with at-home blood collection and high-resolution data